Declotting Devices Market Report 2024

This Declotting Devices industry report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

The declotting devices market size has grown strongly in recent years. It will grow from $2.01 billion in 2023 to $2.13 billion in 2024 at a compound annual growth rate (CAGR) of 6.4%. The growth during the historic period can be attributed to several factors such as increased regulatory approvals and support, the rise of telemedicine, expanded remote monitoring capabilities, the growth of healthcare facilities, and a heightened focus on patient safety regulations.

The declotting devices market size is expected to see strong growth in the next few years. It will grow to $2.75 billion in 2028 at a compound annual growth rate (CAGR) of 6.5%. The projected growth during the forecast period can be attributed to several factors such as increased awareness of vascular health, government initiatives, enhanced healthcare infrastructure, a rising incidence of obesity, and greater adoption of minimally invasive procedures. Key trends for this period include collaborations with technology companies, customization of devices, innovations in anticoagulant therapy, expanding applications of declotting devices, and advancements in medical technology.

The rising incidence of vascular disorders is expected to drive growth in the declotting devices market. Vascular disorders affect blood vessels such as arteries, veins, and capillaries disrupting normal blood flow and potentially leading to various health complications. The increasing prevalence of risk factors such as obesity, sedentary lifestyles, and aging populations is contributing to the rise in vascular disorders. Declotting devices are crucial in treating these conditions by rapidly and effectively removing or dissolving blood clots to restore normal blood flow and prevent complications. For example, a December 2023 report published in the Journal of the American College of Cardiology indicated that in 2022, the prevalence of ischemic stroke in Southeast Asia increased to 9,373,197 cases, with a prevalence rate of 1,358.5, up from 5,994,725 cases in 2021. Thus, the growing incidence of vascular disorders is propelling the declotting devices market.

Leading companies in the declotting devices market are focusing on developing advanced products, such as computer-aided declotting devices (thrombectomy), to improve precision and effectiveness in clot removal procedures. These advanced devices assist in the removal of blood clots from vessels. For instance, in June 2023, Penumbra Inc., a US-based medical device manufacturer, launched Lightning Bolt 7, an advanced arterial declotting (thrombectomy) system. This system introduces modulated aspiration and integrates Penumbra’s Lightning Intelligent Aspiration technology with an advanced microprocessor algorithm. The Lightning Bolt 7 is designed to swiftly extract large, fibrous arterial blood clots with minimal blood loss, addressing acute limb ischemia (ALI), hibernating thrombus, and visceral occlusions, thereby offering a significant advancement in declotting technology.

In September 2021, Abbott Laboratories, a US-based medical device and healthcare company, acquired Walk Vascular LLC for an undisclosed amount. This acquisition complements Abbott’s portfolio of vascular devices, particularly enhancing their peripheral thrombectomy systems. It strengthens Abbott’s ability to offer innovative endovascular therapy solutions and improve patient care. Walk Vascular LLC is known for its advanced thrombectomy systems that specialize in extracting intravascular blood clots through aspiration.

Major companies operating in the declotting devices market are Johnson & Johnson, Abbott Laboratories, Medtronic Ltd, Koninklijke Philips NV, Stryker Corporation, Baxter International Inc, Boston Scientific Corporation, B. Braun Melsungen, Nipro Medical Inc, Teleflex Incorporated, MicroVention Inc, Argon Medical Devices Inc, Surmodics Inc, Balt SAS, Imperative Care Inc, Phenox GmbH, Straub Medical AG, Acandis GmbH & Co KG, Rapid Medical Inc, Thrombolex Inc.

North America was the largest region in the declotting devices market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the declotting devices market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the declotting devices market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Declotting devices are medical instruments designed to remove blood clots (thrombi) from blood vessels in emergency situations where clotting obstructs normal blood flow. These devices are used in conditions such as deep vein thrombosis (DVT), where clots can lead to severe complications such as pulmonary embolism.

The primary types of declotting devices include mechanical declotting devices and embolectomy balloons. A mechanical declotting device is designed to eliminate blood clots from blood vessels through mechanical methods, aiming to restore normal blood flow and prevent complications in conditions such as deep vein thrombosis or pulmonary embolism. Declotting devices encompass thrombectomy devices, such as aspiration thrombectomy devices, percutaneous mechanical thrombectomy devices, and others, and are used in various settings, including hospitals, clinics, and more.

The declotting devices market research report is one of a series of new reports that provides declotting devices market statistics, including declotting devices industry global market size, regional shares, competitors with a declotting devices market share, detailed declotting devices market segments, market trends and opportunities, and any further data you may need to thrive in the declotting devices industry. This declotting devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The declotting devices market consists of sales of ultrasound-assisted thrombolysis devices, hemolytic embolectomy devices, and rotational embolectomy devices. Values in this market are ‘factory gate’ values, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.